Last reviewed · How we verify
Iopidine (APRACLONIDINE)
Iopidine (APRACLONIDINE) is a small molecule alpha-Adrenergic Agonist that targets the Alpha-2A adrenergic receptor. It was originally developed by ALCON and is now owned by Harrow Eye. Iopidine is FDA-approved for various indications including open-angle glaucoma, increased intraocular pressure after ocular procedure, and prevention of cerebral thrombosis. The drug is off-patent, with a single generic manufacturer available. Key safety considerations include the potential for systemic side effects due to its ability to cross the blood-brain barrier.
At a glance
| Generic name | APRACLONIDINE |
|---|---|
| Sponsor | Harrow Health |
| Drug class | alpha-Adrenergic Agonist |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
- Cerebrovascular Occlusion
- Increased Intraocular Pressure after Ocular Procedure
- Open-angle glaucoma
- Percutaneous coronary intervention
- Prevention of Cerebral Thrombosis
- Subacute Stent Thrombosis Prevention
Common side effects
- Dry mouth
- Discomfort
- Hyperemia
- Pruritus
- Tearing
- Blurred vision
- Conjunctivitis
- Discharge
- Dry eye
- Foreign body sensation
- Lid edema
- Abnormal vision
Key clinical trials
- A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness (PHASE3)
- Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis (PHASE4)
- Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma (NA)
- Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis (PHASE2)
- Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma (NA)
- Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension (PHASE3)
- Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iopidine CI brief — competitive landscape report
- Iopidine updates RSS · CI watch RSS
- Harrow Health portfolio CI